AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02035137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Study NCT02325388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ForeSite PT™ system
Description: XSENSOR Technology Corporation's ForeSite PT™ Patient Turn System (referred to as the ForeSite PT™ system) continuously monitors interface pressure and provides CPI that quantifies real-time interface pressure information. It also provides patient turn tracking to assist with management of the patient turn schedule by alerting healthcare providers and/or caregivers to the location of body areas that have experienced the greatest exposure, and when the next turn/repositioning is due as per pre-set alerts.
Study NCT02816138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Open-label transdermal nicotine patch
Study NCT03066050 — intervention group
Intervention type: OTHER
Intervention: MV Repair
Description: Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
Study NCT03066050 — intervention group
Intervention type: OTHER
Intervention: MV Replacement
Description: Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
Study NCT03053791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation in mesencephalic locomotor region
Description: Implantation of Electrodes in the Mesencephalic Locomotor Region for improvement of Locomotion and Gait
Study NCT03053791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of a Deep brain stimulation system
Description: Implantation of a Medtronic Percept PC Impulse Generator for chronic Stimulation of the selected target.
Study NCT03066050 — intervention group
Intervention type: OTHER
Intervention: CABG
Description: Participants underwent coronary artery bypass grafting
Study NCT04133727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of an ageing suit
Description: The simulation suit consists of a pair glasses which simulates narrowing of visual field; a pair of gloves ; a vest ; elbow and knee wraps and sand bags worn on the wrists and ankles
Study NCT04133727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polypharmacy workshop
Description: Participants will conduct a full medication review for older adults within 1 hour and develop a medication list which can be used for counselling of older adults
Study NCT03249155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AO - plus sonification
Description: patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture. Each video-clip is composed by images and sounds of the gestures. The sound of gestures is obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif_example)
Study NCT03249155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CUE - visual and auditory
Description: patients re-learned 8 motor gestures practicing a traditional protocol combining visual and auditory cues
Study NCT00772226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: music pillow
Description: according to randomisation patients will receive with/without music.
Study NCT00772226 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: pillow without music
Description: According to randomisation patients will receive a pillow with/without music
Study NCT03083899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Out-patient clinic on demand (patient-initiated)
Description: Free use of any resources in the out-patient clinic
Study NCT03083899 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scheduled out-patient clinic
Description: Scheduled use of the out-patient clinic
Study NCT01951625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (1.25 mg)
Description: 1.25 mg BAY1021189 tablets
Study NCT01951625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (5 mg)
Description: 5 mg BAY1021189 tablets
Study NCT02406040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
Study NCT01951625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01592370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous (IV) infusion
Study NCT01592370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Administered by IV infusion
Study NCT01592370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Administered by IV infusion
Study NCT01592370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered by IV infusion
Study NCT01592370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Administered PO
Study NCT01592370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered PO and by IV infusion
Study NCT03535337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPS
Description: Assessment of participant's medication adherence and barrier problem solving via phone conversation
Study NCT03535337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS
Description: Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.
Study NCT02099266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Administration of hyperbaric oxygen
Description: Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
Study NCT01561183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect pulp capping (IPC)
Description: Procedure: IPC~The IPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* incomplete removal of carious tissue from the cavity walls~* indirect pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique
Study NCT01561183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct pulp capping (DPC)
Description: Procedure: DPC~The DPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique
Study NCT01561183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Miniature pulpotomy (MP)
Description: Procedure: MP~The MP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* intentionally removal of pulp horn (≈1 mm)~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique
Study NCT01561183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy (FP)
Description: Procedure: FP~The FP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* pulpotomy~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique
Study NCT03799887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 0% unweighed BWSTT
Description: 30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 0% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions).
Study NCT03799887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10% unweighed BWSTT
Description: 30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 10% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions).
Study NCT03799887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20% unweighed BWSTT
Description: 30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 20% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions).
Study NCT00673985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty
Description: Balloon Angioplasty
Study NCT00673985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeStent NT™ Self-Expanding Peripheral Stent
Description: Balloon angioplasty plus stent
Study NCT02454270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 (Dose Escalation): Duvortuxizumab
Description: Participants currently enrolled in the study will continue to receive duvortuxizumab every 14 days (biweekly dosing) in each 28 -day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8 and Day 22, of a 35-day Cycle 1, and then every 14 days in each subsequent 28-day cycle. The cohorts will be opened where participants will receive duvortuxizumab every 7 days (for investigating weekly dosing schedule) in each 28-day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8, Day 15, Day 22, and Day 28 of a 35-day Cycle 1, and then every 7 days in each subsequent 28-day cycle.
Study NCT02454270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (Dose Expansion): Duvortuxizumab
Description: Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.
Study NCT01930084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of care CD4+ after HIV diagnosis
Description: Point of care (POC) CD4+ testing immediately following HIV diagnosis
Study NCT01699269 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: peritumoral glial cell infiltration
Study NCT00806663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib added to FOLFIRI
Description: sunitinib 37 mg once daily (4 weeks on/2 weeks off)
Study NCT02964208 — intervention group
Intervention type: DEVICE
Intervention: AMPLATZER™ LAA Occluder
Description: The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
Study NCT04073004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Resolution Therapy
Description: psychotherapy that includes trance states
Study NCT02430246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Urex Plus
Description: Probiotic
Study NCT02430246 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule without active ingredient
Study NCT02430246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14
Study NCT03189693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVB
Description: nerve stimulator-guided PVB will be performed at two levels
Study NCT03189693 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nerve stimulator-guided PVB containing placebo will be performed at two levels
Study NCT03189693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GA
Description: All patients will receive general anesthesia.
Study NCT06733506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine gluconate (CHG) is a cationic bisguanide that works through disruption of cell membranes. CHG has broad spectrum activity against gram-positive bacteria and to a lesser extent gram negative bacteria. CHG has significant residual activity and addition of alcohol based preparations results in even greater residual activity compared to alcohol alone. CHG acts in the presence of organic material (e.g., blood and biofilm) and its antimicrobial activity is slower than that of alcohols.~Prevantics® 1 ml Swab contains a cutaneous solution of 3.15% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA), which is commonly used for the preparation of a patient's skin prior to surgery or venipuncture. Prevantics® Swab is available as a single use pre-moistened 2-sided applicator (1.0 ml).
Study NCT06733506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isopropyl Alcohol 70% Topical Application Solution
Description: Isopropyl alcohol (IPA), a topical skin disinfectant, is effective against many pathogens and is commonly supplied as 2x2 inch pre-soaked, single-use gauze wipes.
Study NCT06733506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin Prep Before Injecting Recreational/Street Drugs
Description: During a single 10 minute session, a healthcare provider gives the participant verbal and written information, counseling, and training to reinforce participant knowledge, motivation, and skills to practice skin swabbing correctly and routinely before injecting.
Study NCT06733506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prep Before Injecting Recreational/Street Drugs
Description: During a single 10 minute session, a healthcare provider gives the participant verbal and written information, counseling, and training to reinforce participant knowledge, motivation, and skills to practice skin swabbing correctly and routinely before injecting.
Study NCT06732635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Description: Enhanced recovery after surgery (ERAS) programs are designed to achieve early recovery after surgery and a shorter length of stay (LOS) at hospital.
Study NCT01620866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization Reprocessing (EMDR)
Description: EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
Study NCT01385345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 cholecalciferol
Description: High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
Study NCT01385345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 cholecalciferol
Description: High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
Study NCT01436825 — intervention group
Intervention type: DRUG
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
Study NCT02803775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT Algorithm
Description: Programming based on Electrogram measurement
Study NCT01489579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling for Tobacco Cessation
Description: The patients in the Brief, Structured, Telephone (BST) counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout)
Study NCT01489579 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
Study NCT02681913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: This group receives intermittent warm blood cardioplegia enriched with adenosine
Study NCT05090709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Mobilisation Intervention
Description: 30 minutes spinal mobilisations, rate = 0.37Hz, 22 beats per minute, force = less than grade 1, threshold of 80N, location = L1-L5.
Study NCT05090709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Massage
Description: 30 minutes manual touch with no specifications or recordings on rate, pressure or location of touch.
Study NCT04811430 — intervention group
Intervention type: DEVICE
Intervention: Randomized Traditional
Description: Traditional ultrasound guidance was utilized to insert Midlines on simulated veins blocks not live patients
Study NCT04811430 — intervention group
Intervention type: DEVICE
Intervention: Cue(TM) Needle Tracking Technology
Description: Cue(TM) Needle Tracking Technology with real time needle tip tracking is used to assist ultrasound guided midline insertions on simulated veins blocks not live patients
Study NCT04010071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib plus toripalimab
Description: Axitinib 5mg, twice a day, orally, 4 weeks a cycle. Dose reduction from 5mg twice a day to 3mg twice a day should be considered according to adverse events.~Toripalimab 240mg, every 3 weeks, intravenous infused, 6 weeks a cycle. Number of cycle: until disease progression or unacceptable toxicity events.
Study NCT02676102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Generic Video about organ donation
Study NCT02676102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Intervention
Description: an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
Study NCT02676102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Intervention
Description: Videos with content individualized to participant's pre-intervention Organ Donation Belief Index (ODBI).
Study NCT03189693 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GA
Description: All patients will receive general anesthesia.
Study NCT03189693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anesthetic injections
Description: 4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.
Study NCT00976599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 + methotrexate
Description: CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
Study NCT00976599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Methotrexate
Description: Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
Study NCT03984799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Samples obtained during bronchoscopy and blood samples will be evaluated to define inflammatory markers of COPD
Study NCT02468401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Patients planned for coronary angiography or percutaneous coronary intervention will be managed using a protocol that allows us to use minimal volumes of contrast dye
Study NCT02904408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: Group psychotherapy